News
May 22, 2026
Introduction. Heart failure (HF) is a leading cause of hospitalization in Internal Medicine and HF with preserved ejection fraction (HFpEF) accounts for…
May 22, 2026
TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2…
May 21, 2026
AbstractBackgroundIn the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly…
May 21, 2026
join us for an informative, patient-centered webinar featuring cardiology and hematology experts, along with two patients sharing their lived experiences with…
May 21, 2026
AbstractThe therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-…
May 21, 2026
At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…
May 21, 2026
Injectable therapy shows consistent benefits across high-risk ATTR-CM groupsNew analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial…
May 21, 2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –– CR rate now 95% (19 of 20…
May 20, 2026
Multiparametric scores are effective for validating the AL score and increased wall thickness (IWT) scores in AL amyloidosis, according to a study being presented…
May 19, 2026
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics,…